

## Court of Appeal finds abuse of process for second notice of allegation

January 15, 2024

The Federal Court of Appeal (the FCA) [allowed an appeal](#) by Janssen in respect to its motion for summary judgment. The summary judgment motion was based on an argument that it was, *inter alia*, an abuse of process for Apotex to send a notice of allegation (NOA) alleging invalidity of a patent listed on the Patent Register pursuant to the *NOC Regulations* after it had been unsuccessful in respect of non-infringement allegations for the same patent made in a separate NOA (the Prior Action). The Federal Court (the FC) had dismissed the motion for summary judgment, finding that the *NOC Regulations* permit multiple NOAs where one NOA alleges non-infringement and a second one alleges invalidity.

The FCA noted that the doctrine of abuse of process is flexible, without the specific requirements that must be met in respect of other doctrines such as issue estoppel. In particular, the doctrine of abuse of process has been relied upon to prevent re-litigation where issue estoppel requirements were not met.

The FCA also noted the significant amendments made to the *NOC Regulations* in 2017, including the objective to avoid two sets of litigation, namely applications pursuant to the *NOC Regulations* followed by traditional infringement/impeachment actions. In light of these amendments, the FCA opined that the FC should have considered whether a defendant would be able to defend a patent infringement action on the basis of non-infringement and after losing that defence, be allowed to commence a separate impeachment action concerning the same patent. The FCA indicated that such a subsequent action would typically constitute an abuse of process and the same reasoning should apply in respect of separate actions brought pursuant to *the NOC Regulations*.

The FCA rejected Apotex's arguments for why sequential NOAs raising different allegations should be permitted. The FCA also reiterated the flexibility of the abuse of process doctrine by refusing to accept Apotex's argument that there could not be an abuse of process given that the appeal of the Prior Action remains pending. The requirement of finality applies only to issue estoppel. The FCA held that, although requiring all allegations to be raised in the NOA may result in a more complicated proceeding, this would meet the objective of the amendments in 2017 to address all issues in a single action.

The FCA agreed with the parties that the motion should not be remitted to the FC for reconsideration. Accordingly, the FCA considered and decided the motion. The FCA concluded that Apotex's defences are "sufficiently unfair that they are contrary to the interests of justice". Apotex should have raised allegations of invalidity in the Prior Action. The FCA dismissed Apotex's arguments that because the Statement of Claim did not seek a declaration of abuse of process, the motion was ill-founded, finding that the motion was procedural and not substantive. The FCA concluded that the wording of injunctive relief sought by Janssen was appropriate, contrary to Apotex's arguments that it was overbroad.

In conclusion, the FCA allowed the appeal, set aside the FC's judgment on the motion for summary judgment and declared that Apotex's defences are an abuse of process. The FCA granted the relief sought by Janssen, namely the declarations, injunction and costs. Costs of the appeal are to be paid by Apotex.

By

[Chantal Saunders, Beverley Moore](#)

Expertise

[Intellectual Property](#)

---

## **BLG | Canada's Law Firm**

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 800 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](#)

### **BLG Offices**

#### **Calgary**

Centennial Place, East Tower  
520 3rd Avenue S.W.  
Calgary, AB, Canada  
T2P 0R3

T 403.232.9500  
F 403.266.1395

#### **Ottawa**

World Exchange Plaza  
100 Queen Street  
Ottawa, ON, Canada  
K1P 1J9

T 613.237.5160  
F 613.230.8842

#### **Vancouver**

1200 Waterfront Centre  
200 Burrard Street  
Vancouver, BC, Canada  
V7X 1T2

T 604.687.5744  
F 604.687.1415

#### **Montréal**

1000 De La Gauchetière Street West  
Suite 900  
Montréal, QC, Canada  
H3B 5H4

T 514.954.2555  
F 514.879.9015

#### **Toronto**

Bay Adelaide Centre, East Tower  
22 Adelaide Street West  
Toronto, ON, Canada  
M5H 4E3

T 416.367.6000  
F 416.367.6749

situation are considered. You are urged to consult your legal adviser in cases of specific questions or concerns. BLG does not warrant or guarantee the accuracy, currency or completeness of this publication. No part of this publication may be reproduced without prior written permission of Borden Ladner Gervais LLP. If this publication was sent to you by BLG and you do not wish to receive further publications from BLG, you may ask to remove your contact information from our mailing lists by emailing [unsubscribe@blg.com](mailto:unsubscribe@blg.com) or manage your subscription preferences at [blg.com/MyPreferences](http://blg.com/MyPreferences). If you feel you have received this message in error please contact [communications@blg.com](mailto:communications@blg.com). BLG's privacy policy for publications may be found at [blg.com/en/privacy](http://blg.com/en/privacy).

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.